Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Charcot Marie Tooth disease (CMT) is the name of a group of inherited disorders of the nerves in the peripheral nervous system (nerves throughout the body that communicate motor and sensory information to and from the spinal cord) causing weakness and loss of sensation in the limbs.
CMT is named for the three neurologists who first described the condition in the late 1800s. It is also known as hereditary motor and sensory neuropathy, and is sometimes called peroneal muscular atrophy, referring to the muscles in the leg that are often affected. The age of onset of CMT can vary anywhere from young childhood to the 50s or 60s. Symptoms typically begin by the age of 20. For reasons yet unknown, the severity in symptoms can also vary greatly, even among members of the same family.
Although CMT has been described for many years, it is only since the early 1990s that the genetic cause of many of the types of CMT have become known. Therefore, knowledge about CMT has increased dramatically within a short time.
The peripheral nerves
CMT affects the peripheral nerves, those groups of nerve cells carrying information to and from the spinal cord. CMT decreases the ability of these nerves to carry motor commands to muscles, especially those furthest from the spinal cord located in the feet and hands. As a result, the muscles connected to these nerves eventually weaken. CMT also affects the sensory nerves that carry information from the limbs to the brain. Therefore people with CMT also have sensory loss. This causes symptoms such as not being able to tell if something is hot or cold or difficulties with balance.
There are two parts of the nerve that can be affected in CMT. A nerve can be likened to an electrical wire, in which the wire part is the axon of the nerve and the insulation surrounding it is the myelin sheath. The job of the myelin is to help messages travel very fast through the nerves. CMT is usually classified depending on which part of the nerve is affected. People who have problems with the myelin have CMT type 1 and people who have abnormalities of the axon have CMT type 2.
Specialized testing of the nerves, called nerve conduction testing (NCV), can be performed to determine if a person has CMT1 or CMT2. These tests measure the speed at which messages travel through the nerves. In CMT1, the messages move too slowly, but in CMT2 the messages travel at the normal speed.
CMT has been diagnosed in people from all over the world. It occurs in approximately one in 2,500 people, which is about the same incidence as multiple sclerosis. It is the most common type of inherited neurologic condition.
Causes and symptoms
CMT is caused by changes (mutations) in any one of a number of genes that carry the instructions to make the peripheral nerves. Genes contain the instructions for how the body grows and develops before and after a person is born. There are probably at least 15 different genes that can cause CMT. However, as of early 2001, many have not yet been identified.
CMT types 1 and 2 can be broken down into subtypes based upon the gene that is causing CMT. The subtypes are labeled by letters, so there is CMT1A, CMT1B, etc. Therefore, the gene with a mutation that causes CMT1A is different from that that causes CMT1B.
Types of cmt
CMT1A. The most common type of CMT is called CMT1A. It is caused by a mutation in a gene called peripheral myelin protein 22 (PMP22) located on chromosome 17. The job of this gene is to make a protein (PMP22) that makes up part of the myelin. In most people who have CMT, the mutation that causes the condition is a duplication (doubling) of the PMP22 gene. Instead of having two copies of the PMP22 gene (one on each chromosome) there are three copies. It is not known how this extra copy of the PMP22 gene causes the observed symptoms. A small percentage of people with CMT1A do not have a duplication of the PMP22 gene, but rather have a point mutation in the gene. A point mutation is like a typo in the gene that causes it to work incorrectly.
HEREDITARY NEUROPATHY WITH LIABILITY TO PRESSURE PALSIES (HNPP). HNPP is a condition that is also caused by a mutation in the PMP22 gene. The mutation is a deletion. Therefore, there is only one copy of the PMP22 gene instead of two. People who have HNPP may have some of the signs of CMT. However, they also have episodes where they develop weakness and problems with sensation after compression of certain pressure points such as the elbows or knee. Often these symptoms will resolve after a few days or weeks, but sometimes they are permanent.
CMT1B. Another type of CMT, called CMT1B, is caused by a mutation in a gene called myelin protein zero (MPZ) located on chromosome 1. The job of this gene is to make the layers of myelin stick together as they are wrapped around the axon. The mutations in this gene are point mutations because they involve a change (either deletion, substitution, or insertion) at one specific component of a gene.
CMTX. Another type of CMT, called CMTX, is usually considered a subtype of CMT1 because it affects the myelin, but it has a different type of inheritance than type 1 or type 2. In CMTX, the CMT-causing gene is located on the X chromosome and is called connexin 32 (Cx32). The job of this gene is to code for a class of protein called connexins that form tunnels between the layers of myelin.
CMT2. There are at least five different genes that can cause CMT type 2. Therefore, CMT2 has subtypes A, B, C, D and E. As of early 2001, scientists have narrowed in on the location of most of the CMT2 causing genes. However, the specific genes and the mutations have not yet been found for most types. Very recently, the gene for CMT2E has been found. The gene is called neurofilament-light (NF-L). Because it has just been discovered, not much is known about how mutations in this gene cause CMT.
CMT3. In the past a condition called Dejerine-Sottas disease was referred to as CMT3. This is a severe type of CMT in which symptoms begin in infancy or early childhood. It is now known that this is not a separate type of CMT and in fact people who have onset in infancy or early childhood often have mutations in the PMP22 or MPZ genes.
CMT4. CMT4 is a rare type of CMT in which the nerve conduction tests have slow response results. However, it is classified differently from CMT1 because it is passed through families by a different pattern of inheritance. There are five different subtypes and each has only been described in a few families. The symptoms in CMT4 are often severe and other symptoms such as deafness may be present. There are three different genes that have been associated with CMT4 as of early 2001. They are called MTMR2, EGR2, and NDRG1. More research is required to understand how mutations in these genes cause CMT.
CMT1A and 1B, HNPP, and all of the subtypes of CMT2 have autosomal dominant inheritance. Autosomal refers to the first 22 pairs of chromosomes that are the same in males and females. Therefore, males and females are affected equally in these types. In a dominant condition, only one gene of a pair needs to have a mutation in order for a person to have symptoms of the condition. Therefore, anyone who has these types has a 50%, or one in two, chance of passing CMT on to each of their children. This chance is the same for each pregnancy and does not change based on previous children.
CMTX has X-linked inheritance. Since males only have one X chromosome, they only have one copy of the Cx32 gene. Thus, when a male has a mutation in his Cx32 gene, he will have CMT. However, females have two X chromosomes and therefore have two copies of the Cx32 gene. If they have a mutation in one copy of their Cx32 genes, they will only have mild to moderate symptoms of CMT that may go unnoticed. This is because their normal copy of the Cx32 gene does make normal myelin.
Females pass on one or the other of their X chromosomes to their children—sons or daughters. If a woman with a Cx32 mutation passes her normal X chromosome, she will have an unaffected son or daughter who will not pass CMT on to his or her children. If the woman passes the chromosome with Cx32 mutation on she will have an affected son or daughter, although the daughter will be mildly affected or have no symptoms. Therefore, a woman with a Cx32 mutation has a 50%, or a one in two, chance of passing the mutation to her children: a son will be affected, and a daughter may only have mild symptoms.
When males pass on an X chromosome, they have a daughter. When they pass on a Y chromosome, they have a son. Since the Cx32 mutation is on the X chromosome, a man with CMTX will always pass the Cx32 mutation on to his daughters. However, when he has a son, he passes on the Y chromosome, and therefore the son will not be affected. Therefore, an affected male passes the Cx32 gene mutation on to all of his daughters, but to none of his sons.
CMT4 has autosomal recessive inheritance. Males and females are equally affected. In order for a person to have CMT4, they must have a mutation in both of their CMT—causing genes—one inherited from each parent. The parents of an affected person are called carriers. They have one normal copy of the gene and one copy with a mutation. Carriers do not have symptoms of CMT. Two carrier parents have a 25%, or one in four, chance of passing CMT on to each of their children.
The onset of symptoms is highly variable, even among members of the same family. Symptoms usually progress very slowly over a person's lifetime. The main problems caused by CMT are weakness and loss of sensation mainly in the feet and hands. The first symptoms are usually problems with the feet such as high arches and problems with walking and running. Tripping while walking and sprained ankles are common. Muscle loss in the feet and calves leads to "foot drop" where the foot does not lift high enough off the ground when walking. Complaints of cold legs are common, as are cramps in the legs, especially after exercise.
In many people, the fingers and hands eventually become affected. Muscle loss in the hands can make fine movements such as working buttons and zippers difficult. Some patients develop tremor in the upper limbs. Loss of sensation can cause problems such as numbness and the inability to feel if something is hot or cold. Most people with CMT remain able to walk throughout their lives.
Diagnosis of CMT begins with a careful neurological exam to determine the extent and distribution of weakness. A thorough family history should be taken at this time to determine if other people in the family are affected. Testing may also be performed to rule out other causes of neuropathy.
A nerve conduction velocity test should be performed to measure how fast impulses travel through the nerves. This test may show characteristic features of CMT, but it is not diagnostic of CMT. Nerve conduction testing may be combined with electromyography (EMG), an electrical test of the muscles.
A nerve biopsy (removal of a small piece of the nerve) may be performed to look for changes characteristic of CMT. However, this testing is not diagnostic of CMT and is usually not necessary for making a diagnosis.
Definitive diagnosis of CMT is made only by genetic testing, usually performed by drawing a small amount of blood. As of early 2001, testing is available to detect mutations in PMP22, MPZ, Cx32 and EGR2. However, research is progressing rapidly and new testing is often made available every few months. All affected members of a family have the same type of CMT. Therefore once a mutation is found in one affected member, it is possible to test other members who may have symptoms or are at risk of developing CMT.
Testing during pregnancy to determine whether an unborn child is affected is possible if genetic testing in a family has identified a specific CMT-causing mutation. This can be done after 10-12 weeks of pregnancy using a procedure called chorionic villus sampling (CVS). CVS involves removing a tiny piece of the placenta and examining the cells. Testing can also be done by amniocentesis after 16 weeks gestation by removing a small amount of the amniotic fluid surrounding the baby and analyzing the cells in the fluid. Each of these procedures has a small risk of miscarriage associated with it, and those who are interested in learning more should check with their doctor or genetic counselor. Couples interested in these options should obtain genetic counseling to carefully explore all of the benefits and limitations of these procedures.
There is no cure for CMT. However, physical and occupational therapy are an important part of CMT treatment. Physical therapy is used to preserve range of motion and minimize deformity caused by muscle shortening, or contracture. Braces are sometimes used to improve control of the lower extremities that can help tremendously with balance. After wearing braces, people often find that they have more energy because they are using less energy to focus on their walking. Occupational therapy is used to provide devices and techniques that can assist tasks such as dressing, feeding, writing, and other routine activities of daily life. Voice-activated software can also help people who have problems with fine motor control.
It is very important that people with CMT avoid injury that causes them to be immobile for long periods of time. It is often difficult for people with CMT to return to their original strength after injury.
There is a long list of medications that should be avoided if possible by people diagnosed with CMT such as hydralazine (Apresoline), megadoses of vitamin A, B6, and D, Taxol, and large intravenous doses of penicillin. Complete lists are available from the CMT support groups. People considering taking any of these medications should weigh the risks and benefits with their physician.
The symptoms of CMT usually progress slowly over many years, but do not usually shorten life expectancy. The majority of people with CMT do not need to use a wheelchair during their lifetime. Most people with CMT are able to lead full and productive lives despite their physical challenges.
Shy, M. E., J. Kamholz, and R. E. Lovelace, editors. "Charcot-Marie-Tooth Disorders." Annals of the New York Academy of Sciences. 1999.
Keller. M. P., and P. F. Chance. "Inherited peripheral neuropathies." Seminars in Neurology 19, no. 4 (1999): 353-62.
Quest. A magazine for patients available from the Muscular Dystrophy Association.
Charcot Marie Tooth Association (CMTA). 2700 Chestnut Parkway, Chester, PA 19013. (610) 499-9264 or (800) 606-CMTA. Fax: (610) 499-9267. email@example.com. www.charcot-marie-tooth.org.
CMT International. Attn: Linda Crabtree, 1 Springbank Dr. St. Catherine's, ONT L2S2K1. Canada (905) 687-3630. www.cmtint.org.
Muscular Dystrophy Association. 3300 East Sunrise Dr., Tucson, AZ 85718. (520) 529-2000 or (800) 572-1717. http://www.mdausa.org.
Neuropathy Association. 60 E. 42nd St. Suite 942, New York, NY 10165. (212) 692-0662. www.neuropathy.org.
GeneClinics. University of Washington, Seattle. www.geneclinics.org.
HNPP—Hereditary Neuropathy with Liability to Pressure Palsies. http://www.hnpp.org.
OMIM—Online Mendelian Inheritance in Man. www.ncbi.nlm.nih.gov/Omim.
Axon — Skinny, wire-like extension of nerve cells.
Myelin — A fatty sheath surrounding nerves in the peripheral nervous system, which help them conduct impulses more quickly.
Nerve conduction testing — Procedure that measures the speed at which impulses move through the nerves.
Neuropathy — A condition caused by nerve damage. Major symptoms include weakness, numbness, paralysis, or pain in the affected area.
Peripheral nerves — Nerves throughout the body that carry information to and from the spinal cord.